QPPV.COM KNOWLEDGE ASSESSMENT

eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials

Test your understanding of the concepts covered by eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is counting the number of upper-right eDISH subjects insufficient for assessing a drug-level signal?

The upper-right region is unrelated to liver safety Each subject requires medical review, and the denominator, exposure, control findings, and alternative causes affect interpretation Only subjects with normal baseline tests should be counted, regardless of treatment A single confirmed case is always equivalent to ten unreviewed outliers

Question 2 of 10 Which analysis-design decision should be specified before producing an eDISH plot?

The investigator's preferred causality conclusion for each subject The treatment-emergent period and definitions of baseline and maximum laboratory values The number of confirmed Hy's Law cases expected The final regulatory outcome of the development programme

Question 3 of 10 A subject has a peak ALT of 6 times ULN. Subject A had a baseline ALT of 1 times ULN, while Subject B had a stable baseline ALT of 4 times ULN. What is the most appropriate conclusion?

Both subjects necessarily have the same treatment-emergent liver injury Subject B is necessarily more severely injured because the baseline ALT was higher The identical peak relative to ULN may have different meanings, so baseline and longitudinal data must be reviewed Subject A should be excluded because the peak is below 10 times ULN

Question 4 of 10 Why can use of independently determined maximum ALT and bilirubin values be misleading?

The values may have been measured using different units only The two maxima may have occurred at different times and therefore may not represent a concurrent pattern Maximum values cannot be expressed relative to ULN Independent maxima always underestimate the severity of liver injury

Question 5 of 10 What is the purpose of an eDISH-AP analysis as described in the article?

To replace total bilirubin with INR for diagnosing acute liver failure To examine alkaline phosphatase and total bilirubin to help screen for potential cholestatic DILI To assess renal toxicity using alkaline phosphatase as a surrogate To determine whether aminotransferase elevations are treatment-emergent

Question 6 of 10 What is a principal advantage of using a logarithmic scale in an eDISH plot?

It proves that increases are biologically dose-dependent It allows a wide range of laboratory elevations to be displayed without compressing lower values excessively It ensures that maximum ALT and bilirubin values occurred simultaneously It removes the need to document laboratory ULNs

Question 7 of 10 A subject falls in the traditional upper-right eDISH region. What is the most appropriate initial interpretation?

The subject has a confirmed Hy's Law case The subject has acute liver failure The subject is a potential Hy's Law-range subject requiring medical evaluation The investigational product has caused serious hepatotoxicity

Question 8 of 10 What is the main significance of the lower-right Temple's Corollary region?

It identifies bilirubin elevation without aminotransferase elevation It identifies substantial aminotransferase elevation without substantial bilirubin elevation It confirms cholestatic drug-induced liver injury It demonstrates that the investigational product is unrelated to liver-test abnormalities

Question 9 of 10 Which sequence best represents a robust review of a subject identified by eDISH?

Assign causality, then check whether the subject was in the upper-right region Review baseline and chronology, characterise the injury pattern, assess alternative causes, and evaluate clinical course Count the subject in the Hy's Law total without reviewing other data Exclude the subject if symptoms are absent

Question 10 of 10 Which finding would represent a plausible alternative explanation for an upper-right eDISH outlier?

Acute viral hepatitis A documented normal blood pressure A stable non-hepatic laboratory value Absence of a dose relationship alone

eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials

Cookie Settings